Johnson & Johnson (JNJ) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
JNJ Revenue Growth
Revenue Breakdown (FY 2024)
JNJ's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
JNJ Revenue Analysis (2013–2024)
As of May 6, 2026, Johnson & Johnson (JNJ) generated trailing twelve-month (TTM) revenue of $92.15 billion, reflecting solid growth of +6.8% year-over-year. The most recent quarter (Q3 2025) recorded $23.99 billion in revenue, up 1.1% sequentially.
Looking at the longer-term picture, JNJ's 5-year compound annual growth rate (CAGR) stands at +1.6%, indicating moderate growth over time. The company achieved its highest annual revenue of $88.82 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows JNJ's business is primarily driven by Innovative Medicine (64%), and MedTech (36%). With over half of revenue concentrated in Innovative Medicine, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ABT (+6.4% YoY), PFE (+1.4% YoY), and MRK (+1.2% YoY), JNJ has underperformed the peer group in terms of revenue growth. Compare JNJ vs ABT →
JNJ Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| JNJCurrent | $92.1B | +6.8% | +1.6% | 24.9% | |
 ABT | $42.0B | +6.4% | +5.6% | 16.3% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 LLY | $65.2B | +47.4% | +21.6% | 45.6% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% |
JNJ Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $88.82B | +4.3% | $61.35B | 69.1% | $22.15B | 24.9% |
| 2023 | $85.16B | +6.5% | $58.61B | 68.8% | $23.41B | 27.5% |
| 2022 | $79.99B | +1.6% | $55.39B | 69.3% | $21.01B | 26.3% |
| 2021 | $78.74B | -4.7% | $55.34B | 70.3% | $20.94B | 26.6% |
| 2020 | $82.58B | +0.6% | $54.16B | 65.6% | $19.73B | 23.9% |
| 2019 | $82.06B | +0.6% | $54.50B | 66.4% | $20.97B | 25.6% |
| 2018 | $81.58B | +6.7% | $54.49B | 66.8% | $21.18B | 26.0% |
| 2017 | $76.45B | +6.3% | $51.01B | 66.7% | $18.90B | 24.7% |
| 2016 | $71.89B | +2.6% | $50.10B | 69.7% | $20.89B | 29.1% |
| 2015 | $70.07B | -5.7% | $48.54B | 69.3% | $18.29B | 26.1% |
Full JNJ Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy JNJ Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See JNJ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JNJ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare JNJ vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonJNJ — Frequently Asked Questions
Quick answers to the most common questions about buying JNJ stock.
Is JNJ's revenue growth accelerating or slowing?
JNJ maintains +6.8% revenue growth, in line with its 5-year CAGR of +1.6%. TTM revenue stands at $92.1B. Growth rate remains consistent with historical average.
What is JNJ's long-term revenue growth rate?
Johnson & Johnson's 5-year revenue CAGR of +1.6% reflects the sustained expansion pattern. Current YoY growth of +6.8% is near this long-term average.
How is JNJ's revenue distributed by segment?
JNJ reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.